GSK and others’ paroxetine deal broke competition law, tribunal says

GSK and other generic suppliers of paroxetine broke competition law with a “pay for delay” deal on antidepressant paroxetine, the Competition Appeal Tribunal (CAT) has concluded.

GSK_Paroxetine_shutterstock_1313969432_620x413.jpg
The companies had originally been fined almost £45 million by the CMA

Latest from News

More from Clinical